Page last updated: 2024-11-03

probenecid and Leishmaniasis

probenecid has been researched along with Leishmaniasis in 1 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Saenz, RE1
Paz, HM1
Johnson, CM1
Marr, JJ1
Nelson, DJ1
Pattishall, KH1
Rogers, MD1

Trials

1 trial available for probenecid and Leishmaniasis

ArticleYear
Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside.
    The Journal of infectious diseases, 1989, Volume: 160, Issue:1

    Topics: Adult; Allopurinol; Animals; Antiprotozoal Agents; Biopsy; Clinical Trials as Topic; Drug Therapy, C

1989